Is GlaxoSmithKline Playing Defense—or the Opposite?By
It’s hard to look like an innovator when your company has paid a $3 billion fine in the U.S. and is accused of paying another half-billion dollars in bribes to China. But GlaxoSmithKline Chief Executive Officer Andrew Witty is building on a long-term strategy with the move he announced on Tuesday to stop paying staffers for hitting sales targets and doctors for promoting its drugs.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.